EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Statera BioPharma's enterprise value is €0.00 Mil.
Statera BioPharma's EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 was €-16.96 Mil. Therefore, Statera BioPharma's EV-to-EBITDA for today is 0.00.
The historical rank and industry rank for Statera BioPharma's EV-to-EBITDA or its related term are showing as below:
STU:7CB'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -5.98 Med: -4.8 Max: -3.25
Current: -0.37
During the past 3 years, the highest EV-to-EBITDA of Statera BioPharma was -3.25. The lowest was -5.98. And the median was -4.80.
STU:7CB's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 9.67
vs STU:7CB: -0.37
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Statera BioPharma EV-to-EBITDA Historical Data
The historical data trend for Statera BioPharma's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Statera BioPharma's EV-to-EBITDA
For the Biotechnology subindustry, Statera BioPharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Statera BioPharma's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Statera BioPharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Statera BioPharma's EV-to-EBITDA falls into.
Statera BioPharma's current Enterprise Value is €0.00 Mil.
Statera BioPharma's EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-16.96 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Statera BioPharma's PE Ratio for today is calculated as:
Statera BioPharma's share price for today is €0.00.
Statera BioPharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Statera BioPharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STU:7CB has been successfully added to your 